Early detection of chemoradioresponse in esophageal carcinoma by 3′-deoxy-3′-3H-fluorothymidine using preclinical tumor models

Clinical Cancer Research

Volumn 12, Issue 15, 2006, Pages 4590-4597

  Apisarnthanarax, Smith ^a   Alauddin, Mian M ^a   Mourtada, Firas ^a   Ariga, Hisanori ^a   Raju, Uma ^a   Mawlawi, Osama ^a   Han, Dongmei ^a   Bornmann, William G ^a   Ajani, Jaffer A ^a   Milas, Luka ^a   Gelovani, Juri G ^a   Chao, K S Clifford ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE; DOCETAXEL; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; THYMIDINE;

ARTICLE; AUTORADIOGRAPHY; CANCER CELL; CANCER DIAGNOSIS; CELL PROLIFERATION; CONTROLLED STUDY; DRUG UPTAKE; ESOPHAGUS CARCINOMA; EX VIVO STUDY; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGING; IN VITRO STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR MODEL; TUMOR VOLUME; XENOGRAFT;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DIDEOXYNUCLEOSIDES; ESOPHAGEAL NEOPLASMS; FLUORINE RADIOISOTOPES; HUMANS; MALE; MICE; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS; TRITIUM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33748049814     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2720     Document Type: Article

References (46)

1. Urba SG, Orringer MB,Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-13.
2. Swisher SG, Erasmus J, Maish M, et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004;101:1776-85.
3. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001;91:2165-74.
4. Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005;23:4330-7.
5. Westerterp M, van Westreenen HL, Reitsma JB, et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapysystematic review. Radiology 2005;236:841-51.
6. Arslan N, Miller TR, Dehdashti F, Battafarano RJ, Siegel BA. Evaluation of response to neoadjuvanttherapy by quantitative 2-deoxy-2-[18f]fluoro-D- glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol 2002;4:301-10.
7. Kubota R, Yamada S, Kubota K, etal. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-80.
8. Nakamura R, ObaraT, Katsuragawa S, et al. Failure in presumption of residual disease by quantification of FDG uptake in esophageal squamous cell carcinoma immediately after radiotherapy. Radiat Med 2002;20:181-6.
9. Begg AC. Prediction of repopulation rates and radiosensitivity in human tumours. Int J Radiat Biol 1994;65:103-8.
10. Krohn KA, Mankoff DA, Eary JF. Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol 2001;41:96S-103S.
11. Dittmann H, Dohmen BM, Kehlbach R, et al. Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 2002;29:1462-9.
12. Yang YJ, Ryu JS, Kirn SY, et al. Use of 3′-deoxy-3′-[(18)F] fluorothymidine pet to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging 2006;33:412-9.
13. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-6.
14. 3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol 2002;29:281-7.
15. Barthel H, Cleij MC, Collingridge DR, et al. 3′-Deoxy-3′- [18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003;63:3791-8.
16. Leyton J, Latigo JR, Perumal M, et al. Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18f]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 2005;65:4202-10.
17. Sugiyama M, Sakahara H, Sato K, et al. Evaluation of 3′-deoxy- 3′-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med 2004;45:1754-8.
18. Oyama N, Ponde DE, Dence C, et al. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med 2004;45:519-25.
19. Waldherr C, Mellinghoff IK, Tran C, et al. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F- fluorothymidine pet. J Nucl Med 2005;46:114-20.
20. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in a549 carcinoma cells. J Nucl Med 2002;43:1210-7.
21. Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem 1988;263:8350-8.
22. Munch-Petersen B, Cloos L, Jensen HK, Tyrsted G. Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul 1995;35:69-89.
23. Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol 1999;9:12-26.
24. Dunne AL, Mothersill C, Robson T, Wilson GD, Hirst DG. Radiosensitization of colon cancer cell lines by docetaxel: mechanisms of action. Oncol Res 2004;14:447-54.
25. Suzuki M, Nakamatsu K, Kanamori S, Masunaga S, Nishimura Y. Additive effects of radiation and docetaxel on murine sccvii tumors in vivo: special reference to changes in the cell cycle. Radiat Res 2003;159:799-804.
26. Mason KA, Hunter NR, Milas M, Abbruzzese JL, Milas L. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 1997;3:2431-8.
27. Mason KA, Kishi K, Hunter N, et al. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res 1999;5:4191-8.
28. Mason K, Staab A, Hunter N, et al. Enhancement of tumor radioresponse by docetaxel: involvement of immune system. Int J Oncol 2001;18:599-606.
29. Rigas JR, Dragnev KH, Bubis JA. Docetaxel in the treatment of esophageal cancer. Semin Oncol 2005;32:539-51.
30. Pasini F, de Manzoni G, Pedrazzani C, et al. High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. Ann Oncol 2005;16:1133-9.
31. Ajani JA, Fodor MB, Tjulandin SA, et al. Phase ii multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 2005;23:5660-7.
32. Martin SJ, Eisenbarth JA, Wagner-Utermann U, et al. A new precursor for the radiosynthesis of [18F]FLT. Nucl Med Biol 2002;29:263-73.
33. Hughes SJ, Nambu Y, Soldes OS, et al. Fas/apo-1 (cd95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res 1997;57:5571-8.
34. Sasajima T, Miyagawa T, Oku T, et al. Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines. Eur J Nucl Med Mol Imaging 2004;31:1244-56.
35. Key G, Meggetto F, Becker MH, et al. Immunobiochemical characterization of the antigen detected by monoclonal antibody ind.64. Evidence that ind.64 reacts with the cell proliferation associated nuclear antigen previously defined by ki-67. Virchows Arch B Cell Pathol Incl Mol Pathol 1992;62:259-62.
36. Meyn RE, Stephens LC, Hunter NR, Ang KK, Milas L. Reemergence of apoptotic cells between fractionated doses in irradiated murine tumors. Int J Radiat Oncol Biol Phys 1994;30:619-24.
37. Milross CG, Mason KA, Hunter NR, et al. Enhanced radioresponse of paclitaxel-sensitive and -resistant tumours in vivo. Eur J Cancer 1997;33:1299-308.
38. 18F-FDG pet in esophageal cancer. J Nucl Med 2005;46:400-4.
39. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-65.
40. Wieder HA, Brucher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004;22:900-8.
41. 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 2004;45:695-700.
42. 18F-FDG. J Nucl Med 2003;44:1426-31.
43. Francis DL, Freeman A, Visvikis D, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 2003;52:1602-6.
44. Wagner M, Seitz U, Buck A, et al. 3′-[18F]fluoro-3′- deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res 2003;63:2681-7.
45. Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F] FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002;8:3315-23.
46. Cobben DC, Elsinga PH, Suurmeijer AJ, et al. Detection and grading of soft tissue sarcomas of the extremities with (18)F-3′-fluoro-3′- deoxy-L-thymidine. Clin Cancer Res 2004;10:1685-90.